Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 2
1973 2
1975 1
1977 1
1978 2
1980 3
1982 1
1983 2
1984 2
1985 2
1986 3
1987 2
1988 2
1989 8
1990 3
1991 3
1992 1
1993 5
1994 3
1995 4
1996 2
1997 2
1998 1
1999 1
2000 5
2001 2
2002 6
2003 4
2004 6
2005 7
2006 4
2007 2
2008 8
2009 12
2010 5
2011 12
2012 10
2013 8
2014 6
2015 12
2016 16
2017 8
2018 5
2019 7
2020 7
2021 10
2022 6
2023 7
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

219 results

Results by year

Filters applied: . Clear all
Page 1
EULAR revised recommendations for the management of fibromyalgia.
Macfarlane GJ, Kronisch C, Dean LE, Atzeni F, Häuser W, Fluß E, Choy E, Kosek E, Amris K, Branco J, Dincer F, Leino-Arjas P, Longley K, McCarthy GM, Makri S, Perrot S, Sarzi-Puttini P, Taylor A, Jones GT. Macfarlane GJ, et al. Ann Rheum Dis. 2017 Feb;76(2):318-328. doi: 10.1136/annrheumdis-2016-209724. Epub 2016 Jul 4. Ann Rheum Dis. 2017. PMID: 27377815 Free article. Review.
Choosing a skeletal muscle relaxant.
See S, Ginzburg R. See S, et al. Am Fam Physician. 2008 Aug 1;78(3):365-70. Am Fam Physician. 2008. PMID: 18711953 Free article. Review.
Comparison studies have not shown one skeletal muscle relaxant to be superior to another. Cyclobenzaprine is the most heavily studied and has been shown to be effective for various musculoskeletal conditions. The sedative properties of tizanidine and cyclobenzaprine
Comparison studies have not shown one skeletal muscle relaxant to be superior to another. Cyclobenzaprine is the most heavily studied …
Maladaptive plasticity in tinnitus--triggers, mechanisms and treatment.
Shore SE, Roberts LE, Langguth B. Shore SE, et al. Nat Rev Neurol. 2016 Mar;12(3):150-60. doi: 10.1038/nrneurol.2016.12. Epub 2016 Feb 12. Nat Rev Neurol. 2016. PMID: 26868680 Free PMC article. Review.
This Review highlights the links between animal and human studies, and discusses several therapeutic approaches that have been developed to target the neuroplastic changes underlying tinnitus....
This Review highlights the links between animal and human studies, and discusses several therapeutic approaches that have been develo …
Pharmacotherapy for Spine-Related Pain in Older Adults.
Fu JL, Perloff MD. Fu JL, et al. Drugs Aging. 2022 Jul;39(7):523-550. doi: 10.1007/s40266-022-00946-x. Epub 2022 Jun 27. Drugs Aging. 2022. PMID: 35754070 Review.
Whenever possible, beneficial geriatric spine pain pharmacotherapy should employ the lowest therapeutic doses with consideration of polypharmacy, potentially decreased renal and hepatic metabolism, and co-morbid medical disorders. ...They should be used in lower doses with …
Whenever possible, beneficial geriatric spine pain pharmacotherapy should employ the lowest therapeutic doses with consideration of p …
Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review.
Chou R, Peterson K, Helfand M. Chou R, et al. J Pain Symptom Manage. 2004 Aug;28(2):140-75. doi: 10.1016/j.jpainsymman.2004.05.002. J Pain Symptom Manage. 2004. PMID: 15276195 Free article. Review.
Cyclobenzaprine has been evaluated in the most clinical trials and has consistently been found to be effective. ...There is insufficient evidence to determine the relative efficacy or safety of cyclobenzaprine, carisoprodol, orphenadrine, tizanidine, metaxalone, met
Cyclobenzaprine has been evaluated in the most clinical trials and has consistently been found to be effective. ...There is insuffici
Cyclobenzaprine for acute back pain.
Braschi E, Garrison S, Allan GM. Braschi E, et al. Can Fam Physician. 2015 Dec;61(12):1074. Can Fam Physician. 2015. PMID: 26668287 Free PMC article. Review. No abstract available.
Cyclobenzaprine for the treatment of myofascial pain in adults.
Leite FM, Atallah AN, El Dib R, Grossmann E, Januzzi E, Andriolo RB, da Silva EM. Leite FM, et al. Cochrane Database Syst Rev. 2009 Jul 8;2009(3):CD006830. doi: 10.1002/14651858.CD006830.pub3. Cochrane Database Syst Rev. 2009. PMID: 19588406 Free PMC article. Review.
SELECTION CRITERIA: All RCTs and quasi-RCTs reporting use of cyclobenzaprine for treating MP with pain assessment as a primary or secondary outcome. ...AUTHORS' CONCLUSIONS: There was insufficient evidence to support the use of cyclobenzaprine in the treatment of MP …
SELECTION CRITERIA: All RCTs and quasi-RCTs reporting use of cyclobenzaprine for treating MP with pain assessment as a primary or sec …
Cyclobenzaprine overdosage.
Linden CH, Mitchiner JC, Lindzon RD, Rumack BH. Linden CH, et al. J Toxicol Clin Toxicol. 1983 May;20(3):281-8. doi: 10.3109/15563658308990071. J Toxicol Clin Toxicol. 1983. PMID: 6620442
The clinical findings in three patients who ingested 260-900 mg cyclobenzaprine (Flexeril) consisted of delayed onset and long duration of anticholinergic symptomatology. ...The pharmacological properties of cyclobenzaprine may account for the observed toxicity....
The clinical findings in three patients who ingested 260-900 mg cyclobenzaprine (Flexeril) consisted of delayed onset and long durati …
Pharmacokinetic profile of once-daily cyclobenzaprine extended-release.
Darwish M, Hellriegel ET. Darwish M, et al. Expert Opin Drug Metab Toxicol. 2010 Nov;6(11):1425-36. doi: 10.1517/17425255.2010.523419. Epub 2010 Sep 30. Expert Opin Drug Metab Toxicol. 2010. PMID: 20883117 Review.
This review focuses on the pharmacokinetic profile of a new formulation, cyclobenzaprine extended-release (CER), which delivers a sustained plasma cyclobenzaprine concentration over 24 h, allowing once-daily dosing. ...CER was characterized by a single daily peak in …
This review focuses on the pharmacokinetic profile of a new formulation, cyclobenzaprine extended-release (CER), which delivers a sus …
219 results